Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XmAb13676 |
Synonyms | |
Therapy Description |
XmAb13676 (Plamotamab) is a bispecific monoclonal antibody that targets CD20-expressing B cells and CD3-expressing T cells, and once bound may potentially result in T-cell mediated cytotoxicity of tumor cells (Blood 2014 124:3111). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XmAb13676 | Plamotamab | CD20 Antibody 24 CD3 Antibody 99 | XmAb13676 (Plamotamab) is a bispecific monoclonal antibody that targets CD20-expressing B cells and CD3-expressing T cells, and once bound may potentially result in T-cell mediated cytotoxicity of tumor cells (Blood 2014 124:3111). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02924402 | Phase I | XmAb13676 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies | Completed | USA | GBR | FRA | 1 |